GSK plc American Depositary Shares (Each representing two Ordinary Shares) (GSK) — Analysis Summary
GSK plc American Depositary Shares (Each representing two Ordinary Shares) (GSK) has a market cap of $100.28B with year-over-year revenue growth of +7.5%. Net margin stands at 19.3%. The stock trades at a P/E ratio of 12.1.
Key Takeaways
- Revenue changed +7.5% year-over-year
- Net margin of 19.3%
- P/E ratio of 12.1
Compared with its sector, GSK posted revenue growth of +7.5% and trades at a P/E of 12.1.
GSK plc American Depositary Shares (Each representing two Ordinary Shares) (GSK)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsWatch List
Some caution signals are active and should be weighed alongside the valuation work.
Current ratio at 0.82x — current liabilities exceed current assets
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Employees
66,841
Exchange
XNYS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Annual Dividend/Share
$1.81
Dividend Yield
3.61%
Dividend History
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.